Loading...
Market
What will be CASGEVY™'s market share in CRISPR-based therapy by end of 2024?
2
Resolution / Starting Odds
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Market analysis reports from reputable firms
Story
CASGEVY™ CRISPR-Based Therapy for Beta Thalassemia Approved in England
Aug 7, 2024, 11:25 PM
Patients in England suffering from a rare blood disorder known as transfusion-dependent beta thalassemia will soon have access to the world's first CRISPR-based medicine, CASGEVY™. This development follows a reimbursement agreement reached between Vertex Pharmaceuticals and U.K. officials. The National Health Service (NHS) will begin rolling out the gene therapy, which is a collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics, marking a significant advancement in the treatment of this condition.
View original story
Similar markets
Less than 20% • 25%
20% to 40% • 25%
41% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Company A exceeds $10 billion • 25%
Company B exceeds $10 billion • 25%
Both companies exceed $10 billion • 25%
Neither company exceeds $10 billion • 25%
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%
0-10% • 25%
11-25% • 25%
26-50% • 25%
51%+ • 25%
Below 5% • 25%
5%-10% • 25%
10%-15% • 25%
Above 15% • 25%
Editas Medicine • 25%
Intellia Therapeutics • 25%
CRISPR Therapeutics • 25%
Other • 25%
Increase by more than 5% • 25%
Increase by 0-5% • 25%
No change • 25%
Decrease • 25%
Yes • 50%
No • 50%
NTLA-2002 • 25%
Editas Medicine Therapy • 25%
Beam Therapeutics Therapy • 25%
Other • 25%
Less than 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
More than 75% • 25%